POTELIGEO Treatment in Patients with Relapsed or Refractory Mycosis Fungoides (MF) or Sezary Syndrome (SS) After at Least one Prior Systemic Therapy
-
- STATUS
- None
Updated on 19 February 2024
Summary
The main puropose of the expanded access program is to facilitate access to POTELIGEO for patients who lack therapeutic alternatives and in which there is a reasonable expectation that the provision of access to POTELIGEO will have a positive benefit/risk for the patient during the time between commercial approval by the FDA and the date of availability of commercial supply to patients. Permission to use this investigational drug by the FDA is limited to our one single patient.
Details
| Condition | TBD |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | TBD |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.